Clinical trials: Human Influenza
Influenza, Human
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
The purpose of this study is to test the safety and efficacy of zanamivir given intravenously and how well it works at two different doses in hospitalized adolescents and adults with flu.
- Trial name
- ZORO (NCT01231620)
- Testing
- Zanamivir, Oseltamivir
- Where
- 170 sites in United States, Australia and 26 more
- Volunteers
- 626 people
- Sponsor
- GlaxoSmithKline
H1N1 Influenza Virus
Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma
The purpose of this study is to assess the safety and the body's immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in people with asthma.
- Trial name
- NCT00978120
- Testing
- H1N1 vaccine high dose, H1N1 vaccine low dose
- Where
- 7 sites in United States
- Volunteers
- 390 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Swine-origin A/H1N1 Influenza
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine. Primary Objectives: To describe the immunogenicity of the candidate vaccines after each injection.
- Trial name
- NCT00953524
- Testing
- Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)
- Where
- 15 sites in United States
- Volunteers
- 849 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP
This randomized, double-blinded trial will assess humoral immune responses to adjuvanted, egg-based quadrivalent influenza vaccines compared to standard dose, egg-based quadrivalent influenza vaccines among healthcare personnel…
- Trial name
- EDUCATE (NCT06054269)
- Testing
- FLUAD Quadrivalent, FluQuadri
- Where
- 2 sites in Peru
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Seasonal Influenza
A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1020, mRNA-1030, and mRNA-1010 vaccines against vaccine-matched influenza A and B strains.
- Trial name
- NCT05333289
- Testing
- mRNA-1030, mRNA-1020, mRNA-1010
- Where
- 15 sites in United States
- Volunteers
- 572 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza, Influenza Immunisation
Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine
This is a Phase II randomized, double-blind, placebo-controlled trial in 120 males and non-pregnant females, 18 to 49 years old, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03058692
- Testing
- Influenza Multimeric-001 Vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Indonesia/05/2005 (H5N1) administered at 3 dose levels in adjuvanted (SE) rHA…
- Trial name
- PSC25 (NCT01612000)
- Testing
- PanBlok, rHA adjuvant
- Where
- 5 sites in United States
- Volunteers
- 341 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza A H3N2
Assessment of Wearable Sensors During Experimental Human Influenza Infection (Sigma Plus)
The aim of the study is to investigate disease in volunteers deliberately infected with influenza A(H3N2), including biological markers of inflammation and immune response, and changes in physiological parameters including heart…
- Trial name
- NCT04204993
- Testing
- Lumee Oxygen Platform
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Imperial College London
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
The purpose of this study is to evaluate the immunogenicity and safety of 13-valent pneumococcal polysaccharide vaccine when given concomitantly with seasonal inactivated influenza vaccine to adults 50 years and older who have…
- Trial name
- NCT02124161
- Testing
- 13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine
- Where
- 44 sites in United States
- Volunteers
- 882 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults
The purpose of this study was to expand the data describing the safety profile of FluMist in the indicated populations (5-8, 9-17, and 18-49 years of age) and to assess the safety of annual revaccination in those who received…
- Trial name
- NCT00113880
- Testing
- FluMist
- Where
- 77 sites in United States
- Volunteers
- 63,061 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza Virus Vaccine
Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study
Some people experience symptoms just after receiving the seasonal inactivated influenza vaccine. The cause of some of these symptoms is likely to be an immune response to the vaccine.
- Trial name
- NCT01522248
- Testing
- Trivalent Inactivated Influenza vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Healthy
A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)
A phase I/II, randomized, single-blind, placebo-controlled escalating double-dose safety study of an intramuscular universal influenza vaccine (Multimeric-001) injected to healthy volunteers.
- Trial name
- NCT00877448
- Testing
- Adjuvanted Multimeric-001 250 Mcg, Multimeric-001 250 Mcg, Phosphate Buffered saline
- Where
- Israel
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Influenza
A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV
The objective of this pilot study is to assess the immunogenicity and reactogenicity of Fluzone High Dose with Fluzone (standard adult dose) influenza vaccines in healthcare workers.
- Trial name
- NCT02263040
- Testing
- Fluzone High-Dose, Fluzone (standard dose)
- Where
- Canada
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Mount Sinai Hospital, Canada
Haemophilus Influenza Type b
Exploratory Clinical Study of MT-2301
The purpose of this study is to evaluate efficacy and safety of MT-2301 when co-administered with DPT-IPV using ActHIB® as a control in healthy infants.
- Trial name
- NCT02140047
- Testing
- Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV, Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV, Haemophilus influenza type b conjugate vaccine + DPT-IPV
- Where
- Japan
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Influenza
Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza
This study is a randomized, blinded, placebo-controlled clinical efficacy trial to assess the duration and severity of influenza symptoms, and duration of viral shedding, in influenza patients receiving oseltamivir early and late…
- Trial name
- NCT00555893
- Testing
- Oseltamivir
- Where
- United States
- Volunteers
- 194 people
- Sponsor
- Marshfield Clinic Research Foundation
Pandemic H5N1 Influenza
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in elderly subjects
- Trial name
- NCT01766921
- Testing
- Adjuvanted H5N1 pandemic influenza vaccine
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 1,393 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
This study is designed to test the immunogenicity and reactogenicity of the Fluarix™/Influsplit SSW® influenza vaccine containing the influenza strains recommended for the 2010-2011 season.
- Trial name
- NCT01144299
- Testing
- Fluarix™/Influsplit SSW®
- Where
- 6 sites in Germany
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immune Response
Open-Label Influenza Vaccine Evaluation
This is an open-label, randomized trial in up to 210 adults aged 65-74 years to evaluate the immune response to consecutive influenza vaccination across 2 seasons.
- Trial name
- OLIVE (NCT02872311)
- Testing
- High Dose Influenza vaccine, Adjuvanted Influenza vaccine, Standard Dose Influenza vaccine
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Marshfield Clinic Research Foundation
Influenza
Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine
To observe and to describe the safety during Days 0 to 21 following injection of the 2004-2005 formulation of the inactivated, split-virion influenza vaccine Fluzone® in subjects aged 18-59 years and subjects aged ≥ 60 years.
- Trial name
- NCT00831987
- Testing
- Fluzone®: Influenza virus vaccine 2004-2005 formulation
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
A Phase III, Randomized, Observer-Blind, Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator…
- Trial name
- NCT02587221
- Testing
- MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV), Non-Influenza Comparator (Boostrix)
- Where
- 89 sites in Bulgaria, Colombia and 10 more
- Volunteers
- 6,790 people, healthy volunteers welcome
- Sponsor
- Seqirus